ABSTRACT
B Conclusions: b Most pharmacists agree NMBI infusions in ARDS are best reserved until after trials of deep sedation or proning. For COVID+ ARDS patients, few respondents felt any of the following were very/extremely important reasons for NMBI initiation: reduced self-extubation and COVID aerosolization exposure during reintubation 8(6%) or reduced sedative use during shortages 8(6%). B Introduction: b In the face of the COVID pandemic, and recent evidence and practice guidelines surrounding neuromuscular infusion (NMBI) use during ARDS, the practices/perceptions of ICU pharmacists regarding NMBI use during ARDS may not be evidence-based. [Extracted from the article] Copyright of Critical Care Medicine is the property of Lippincott Williams & Wilkins and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full . (Copyright applies to all s.)